Arbutus Biopharma Corp SEC filings ABUS
Arbutus Biopharma Corp has 1,000 filings in SEC EDGAR's recent list, going back to Aug 9, 2011. Its latest annual report, Form 10-K, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SC TO-I/A | Filing | Oct 1, 2026 | — |
| SC TO-I/A | Filing | Sep 30, 2026 | — |
| SC TO-I | Filing | Aug 24, 2026 | — |
| SC TO-C | Filing | Aug 21, 2026 | — |
| EFFECT | Filing | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Dec 2, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2024 | — |
| D | Filing | Dec 30, 2021 | — |
| EFFECT | Filing | Nov 18, 2021 | — |
| CORRESP | Letter to the SEC | Nov 16, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2021 | — |
| EFFECT | Filing | Oct 22, 2020 | — |
| CORRESP | Letter to the SEC | Oct 21, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 3, 2020 | — |
| CT ORDER | Filing | Sep 1, 2020 | — |
| CT ORDER | Filing | Jul 23, 2020 | — |
| EFFECT | Filing | Jan 10, 2020 | — |
| CORRESP | Letter to the SEC | Jan 8, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2017 | — |
| PRER14A | Pre 14a special meeting nov 2017 | Nov 21, 2017 | — |
| CORRESP | Letter to the SEC | Nov 20, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2017 | — |
| CT ORDER | Filing | Jun 9, 2017 | — |
| NT 10-K | Filing | Mar 16, 2017 | Mar 16, 2017 |
| EFFECT | Filing | Jan 19, 2017 | — |
| CORRESP | Letter to the SEC | Jan 17, 2017 | — |
| CT ORDER | Filing | Jan 6, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2016 | — |
| CORRESP | Letter to the SEC | Oct 17, 2016 | — |
| CORRESP | Letter to the SEC | Sep 29, 2016 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2016 | — |
| CT ORDER | Filing | Sep 19, 2016 | — |
| CT ORDER | Filing | Apr 21, 2016 | — |
| CT ORDER | Filing | Nov 23, 2015 | — |
| CT ORDER | Filing | Sep 21, 2015 | — |
| CT ORDER | Filing | Jul 31, 2015 | — |
| DEFR14A | Form defr14a | Jun 5, 2015 | — |
| CT ORDER | Filing | May 6, 2015 | — |
| EFFECT | Filing | Dec 11, 2014 | — |
| CT ORDER | Filing | Dec 5, 2014 | — |
| CT ORDER | Filing | Sep 29, 2014 | — |
| CT ORDER | Filing | Jun 23, 2014 | — |
| SUPPL | Filing | Mar 13, 2014 | — |
| SUPPL | Filing | Mar 10, 2014 | — |
| EFFECT | Filing | Feb 28, 2014 | — |
| CT ORDER | Filing | Nov 20, 2013 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2013 | — |
| SUPPL | Filing | Oct 17, 2013 | — |
| SUPPL | Filing | Oct 16, 2013 | — |
| CORRESP | Letter to the SEC | Oct 7, 2013 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2013 | — |
| CORRESP | Letter to the SEC | Sep 12, 2013 | — |
| CORRESP | Letter to the SEC | Sep 6, 2013 | — |
| CORRESP | Letter to the SEC | Aug 15, 2013 | — |
| UPLOAD | Letter from the SEC | Aug 9, 2013 | — |
| EFFECT | Filing | Jan 17, 2013 | — |
| CT ORDER | Filing | Jun 5, 2012 | — |
| CT ORDER | Filing | Feb 9, 2012 | — |
Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABUS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Warminster, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1447028
- Former names
- TEKMIRA PHARMACEUTICALS CORP (until Aug 3, 2015); TEKMIRA PHARMACEUTICALS Corp (until Aug 3, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.